FDA — authorised 13 May 2011
- Application: NDA202258
- Marketing authorisation holder: MERCK SHARP DOHME
- Local brand name: VICTRELIS
- Indication: CAPSULE — ORAL
- Status: approved
🇺🇸 Cross-Over Boceprevir Treatment in United States
FDA authorised Cross-Over Boceprevir Treatment on 13 May 2011
Marketing authorisation
Cross-Over Boceprevir Treatment in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Virology / Hepatology approved in United States
Frequently asked questions
Is Cross-Over Boceprevir Treatment approved in United States?
Yes. FDA authorised it on 13 May 2011.
Who is the marketing authorisation holder for Cross-Over Boceprevir Treatment in United States?
MERCK SHARP DOHME holds the US marketing authorisation.